restricted the analysis to those aged between 20 and 75 years when starting RRT between 1975 and 1992. In addition we limited the analysis to two diagnostic groups, the major standard causes of primary renal disease (PRD), which are restricted the data used to European Union ( EU ) countries given EDTA codes 00-49 and diabetes (EDTA codes 80-81). only. EDTA codes 00-49 include all primary glomerulonephritis, All data analysis was performed using the features of the pyelonephritis, interstitial nephritis and polycystic kidneys SPSS statistical package. This program provides a straightbut not renal failure secondary to vascular or systemic forward analysis of survival by Life Tables. The Wilcoxon  disease. (Gehan) test was used to analyse survival of the subgroups. First treatment was haemodialysis (HD), or peritoneal The Cox regression analysis that enables adjustments to be dialysis (PD), i.e. pre-emptive transplantation patients are made for covariates such as age and diagnosis when comparnot included. Patients who were treated with dialysis when ing sub-groups within the cohort was also used. However, entering RRT but later received renal allografts are included Cox regression can be invalid, in particular when analysing in the survival analysis in the same way as those patients covariates that are not linear or constant over time [4] . who have remained on dialysis. Censoring took place at the Therefore we have presented the survival analysis in two end of the observation period or, for lost to follow-up ways, as conventional actuarial survival curves for certain individuals, at the day after that the patient was confirmed strata of the examined cohort and also as relative hazard as being alive usually by 31 December each year.
risks as calculated by Cox regression. Reporting to the ERA-EDTA Registry became much less complete during the mid-1990s. This is illustrated in Figure 1 .
The percentage of lost-to-follow-up (LTFU ) patients Results increases with time of follow-up in all subgroups of patients i.e. those starting in 1975, 1980, 1985 and 1990 . In particular for patients who started RRT in 1990 there was already a Figure 2 shows the actuarial survival of patients with high percentage of lost-to-follow-up by 3 years, i.e. more standard PRD aged 40-49 years, starting HD during than 20%. A small number of lost-to-follow-up patients is two time periods, 1975-1979 (n=8833) and [1985] [1986] [1987] [1988] [1989] acceptable but when the rate increase above 10-15% it is not (n=11484). There is an improvement in survival, from possible to make any analysis or interpretations with accu-67 to 77% at 5 years when the later cohort (1985) (1986) (1987) (1988) (1989) racy. As the returns of data after 1992 are less good we is compared to the former (1975) (1976) (1977) (1978) (1979) . For patients decided to end the analysis at this year. Table 1 shows the with the same age (40-49) and diagnosis (standard total number of patients included in this analysis, altogether PRD) who started PD, survival during the same timeclose to a quarter of a million. In order to get a more periods (1975-1979, n=1186 and 1985-1989, n=1523) homogenous population we have in a few of the analyses increased from 60 to 77% respectively, i.e. to the same level as with HD ( Figure 3) . Figure 4 shows a comparison of the survival of constitute alternative determinants and may act as confounders. We therefore proceeded with a proporpatients aged 60-69 years, with standard PRD who started RRT between 1985 and 1989 with HD (n=14 tional hazard analysis, i.e. Cox regression [4] . The following variables were included in the hazard ana-438) or PD (n=2789). Patients who started with HD have a higher 5-year survival of 53% than those lysis: gender, age, treatment modality, year of starting RRT and diagnosis (standard PRD or diabetes). In commencing with PD (44%). For patients of the same age group (60-69 years) with diabetes who started order to get a more homogenous sample a separate analysis was also made for EU countries only. with HD (n=3513) between 1985 and 1989 the 5-year survival was again somewhat better than for those who Figure 7 presents the relative risk (RR) for mortality for one determinant while the other ones are adjusted started with PD (n=996), namely 24% and 15% for HD and PD respectively ( Figure 5 ). Figure 6 summar-and controlled for. The RR for PD compared to HD is higher at 1.25 (95% CI; 1.23-1.27), i.e. it indicates izes the 5-year survival of all patients starting treatment with HD and with PD who had standard PRD or a 25% higher risk of death for patients who started treatment with PD compared with HD. Likewise the diabetes in two age groups namely 20-75 years and 60-69 years, for the whole period of analysis from RR of 1.045 (95% CI; 1.044-1.046) for age means that the relative risk of death increases by 5% for each 1975 to 1992. For all the patient groups with the exception of those with diabetes aged 20-75 years, 1-year increase in age. Woman have a slightly (5%) higher mortality than men, RR 1.046 (95% CI; those starting treatment with HD have a better survival than those starting with PD.
1.040-1.053), i.e. a 5% increase in risk. Patients with diabetes have a considerably higher mortality than This conventional survival analysis of age strata, diagnosis and time-periods of starting RRT of the those with standard PRD with a RR of 2.46 (95% CI; 2.42-2.50) (not shown in Figure 7 ). The RR of 0.958 whole cohort show that age, mode of renal replacement therapy (MOT ), year of starting treatment, and cause (95% CI; 0.957-0.960) for the year of starting RRT is the most interesting finding, indicating that mortality of renal disease influence survival. These factors thus risk, whereas a more recent year of starting treatment has decreased by about 4% with each calendar year of appeared to be beneficial. It is worth noting that the starting RRT.
difference between PD and HD is less prominent in The effect of age within the range of 20-75 years at the later part of the observation period. For patients the start of RRT and of calendar year (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) starting RRT during 1975-1983 the RR of death for were analysed separately for different subsets of PD compared with HD was 1.32 (95% CI; 1.28-1.34) patients, namely all patients, those with standard PRD and for 1984-1992 it was 1.18 (95% CI; 1.16-1.21). receiving HD and PD and those with diabetes receiving these two types of treatment ( Figure 8 ). The impact of age and year of starting RRT is similar in all subsets and is higher than that reported from the US Renal Data System although lower than the figures reported from Japan. Five-year survival of all patients starting RRT during 1982-1987 in the USA was 40%, in Europe 59%, and in Japan 61%. For non-diabetic patients aged 45-54 years in these three geographical areas, the 5-year survival was 58, 66, and 72% respectively [5] . The higher mortality among RRT patients in the USA as compared to Europe can probably be explained to a considerable extent, if not entirely, by a higher Fig. 8 . The adjusted relative risk (RR) of death in different groups prevalence of co-morbidities in the US dialysis populaof patients starting RRT related to increasing age by annual increments and calendar year of starting treatment.
tion [6 ] . Relatively large differences in the survival of
patients were censored at the date of transplantation taken into account [7] .
Another interesting observation is the higher mortal-that would most probably decrease the overall survival as transplanted patients demonstrate a superior surity of patients who start RRT with PD as compared to HD. A relative risk of 1.25 is not as high as, for vival, at least in the long term [17] . We would be left with a selection of RRT patients waiting for a renal example, the risk from diabetes, which in this study gave a RR around 2.5, or age that gave a RR of about transplant, not accepted for transplantation, and a few not interested to become transplanted. This would give 1.05 per increment of 1 year. For a RR of 1.05, on a yearly basis, it can be deduced that an increase in age a more than appropriately gloomy outlook for a typical patient entering RRT with dialysis, where transplantaof 10 years would increase risk by the order of 1.6. This difference between PD and HD is worth com-tion is a possibility. We have examined the annual rate of transplantation in our cohort and it is very low at menting on as the long-term efficacy of these two treatment modalities has been discussed and compared around 1-2%, and this rate did not change much over the observation period (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) . Thus an increased on many occasions [8, 9] . In general our observations agree with those in other analyses when it has not been rate of transplantation cannot account for the improvement we have observed in the survival of RRT patients, possible to fully adjust for case mix and co-morbidities [10, 11, 12] . Bloembergen et al. [13] compared mortality which is the most important message from this study.
Differences in transplantation rates may, however, be between prevalent patients treated with HD and PD in the USA. The age-adjusted mortality was higher in part of the explanation for differences in survival of patients who started PD or HD, and we have not been prevalent PD patients compared with HD patients during 1987-1989, the RR being 1.11 for all primary able to examine this. Likewise the unexpected slightly better survival of men versus women may perhaps be renal diseases excluding diabetes and 1.38 for diabetes. On the other hand Fenton et al. [14] from Canada, in explained by a higher transplantation rate for men.
The objective of this study has not been primarily an extensive follow-up of more than ten thousand patients who began RRT with PD or HD, found no to compare different modes of RRT but rather to examine the prognosis of a patient with end-stage renal significant difference in survival between PD and HD, although with a trend towards better survival with PD. disease who presented to a nephrologist in the late 1970s as compared to the early 1990s, irrespective of Likewise no difference in the survival of PD and HD treated patients was found in an Italian study where what mode of RRT treatment was available and was provided. Whatever statistical method we use, whether 102 HD and PD patients were followed prospectively for 3 years [15] . Furthermore, in a more recent reas-conventional survival analysis with survival curves related to age, diagnosis and time-period of the cohort sessment of survival among incident patients entering RRT with PD or HD after 1989 in the USA, no ( Figures 2-5) or the Cox hazard regression model ( Figures 6-9 ) the results are in agreement, showing significant differences were seen between the treatment modalities [16 ] .
that survival on RRT in Europe has improved between 1975 and 1992. It would be interesting to know what It is likely that if we had been able to study patients who commenced PD and HD since 1990, we would has happened to patient survival since 1992, and future studies will hopefully investigate this issue based on have found a higher proportion of PD patients and a further decrease in the difference in survival between up-dated Registry data of good quality. those on PD and HD [15] . The data presented here are to some extent 'historical' as the follow-up was terminated in 1992 and most of the data comes from References the 1980s. In addition we have shown that the observed differences in survival between PD and HD decreased 1. Mallik NP, Jones E, Selwood N. The EDTA-ERA Registry. Am with time. It should also be remembered that this
